- Home
- RNXT
RNXT
RenovoRx Inc.
as of 03-09-2026 11:30am EST
$0.81
+$0.02
+2.28%
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 37.4M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 200.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | 59.60 |
| 52 Week Low/High: | $0.70 - $1.45 | Next Earning Date: | N/A |
| Revenue: | $43,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2995.35% | Revenue Growth (next year): | 219.61% |
| P/E Ratio: | -3.30 | Index: | N/A |
| Free Cash Flow: | -9137000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of RenovoRx Inc. (RNXT)
Agah Ramtin
Buy
Chief Medical Officer
RNXT Jan 21, 2026
Avg Cost/Share
$1.00
Shares
10,000
Total Value
$9,975.00
Owned After
798,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Dec 31, 2025
Avg Cost/Share
$0.86
Shares
9,795
Total Value
$8,423.70
Owned After
798,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Dec 30, 2025
Avg Cost/Share
$0.83
Shares
205
Total Value
$169.33
Owned After
798,460
SEC Form 4
Bagai Shaun
Buy
Chief Executive Officer
RNXT Dec 18, 2025
Avg Cost/Share
$0.90
Shares
5,000
Total Value
$4,506.50
Owned After
340,040
SEC Form 4
Bagai Shaun
Buy
Chief Executive Officer
RNXT Dec 17, 2025
Avg Cost/Share
$0.85
Shares
5,000
Total Value
$4,262.00
Owned After
340,040
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Dec 16, 2025
Avg Cost/Share
$0.85
Shares
12,000
Total Value
$10,200.00
Owned After
798,460
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Agah Ramtin | RNXT | Chief Medical Officer | Jan 21, 2026 | Buy | $1.00 | 10,000 | $9,975.00 | 798,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Dec 31, 2025 | Buy | $0.86 | 9,795 | $8,423.70 | 798,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Dec 30, 2025 | Buy | $0.83 | 205 | $169.33 | 798,460 | |
| Bagai Shaun | RNXT | Chief Executive Officer | Dec 18, 2025 | Buy | $0.90 | 5,000 | $4,506.50 | 340,040 | |
| Bagai Shaun | RNXT | Chief Executive Officer | Dec 17, 2025 | Buy | $0.85 | 5,000 | $4,262.00 | 340,040 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Dec 16, 2025 | Buy | $0.85 | 12,000 | $10,200.00 | 798,460 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 13, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 13, 2025 · 100% conf.
AI Prediction SELL
1D
-3.50%
$0.94
Act: -23.03%
5D
-14.82%
$0.83
Act: -20.11%
20D
-5.84%
$0.92
Act: -1.48%
Price: $0.97 Prob +5D: 0% AUC: 1.000
0001493152-25-022325
Transcript text not available. View on SEC.gov →
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 14, 2025
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 15, 2025
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Compare RNXT vs Leading Stocks
See how RNXT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.